RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
Trial details
- Registry ID
- NCT06146101
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Phase 2 Investigational Product - IHL-42X High dose
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101 | Incannex Healthcare Ltd | Phase 2, Phase 3 | Completed | 2025-05-20Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |